Advisors

ReceptoPharm maintains collaborative and research relationships with a number of noted academic researchers associated with the National Institutes of Health (NIH), Harvard University, Massachusetts General Hospital, Yale University, Stanford University, Baylor College of Medicine, the University of Saskatchewan, Soochow University, the University of Dundee and USAMRIID of the Department of Defense.

Clinical development links have been established not only within the US but also within China, the U.K., and Canada to augment ReceptoPharm's internal research and development efforts. All the researchers involved are recognized experts in their respective fields, have proven credentials as well as histories of successful grant applications, and recognition from academia and government agencies administering these research programs. Some of these researchers have become members of ReceptoPharm's Scientific Board of Advisors.

Scientific Advisory Board

Dorothy Bray, Ph.D., is a Clinical/Research Development Consultant with nine years experience working in HIV research and development with GlaxoSmithKline plc (previously Glaxo Wellcome), the largest provider of HIV antiretroviral drugs with an estimated 40% global market share. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs. Her key skills include broad scientific and regulatory knowledge, strategic planning, and commercial awareness. Dr. Bray had global responsibility for clinical trials program for her most recent position as Director, Clinical Development HIV, GlaxoSmithKline, UK. She holds a Ph.D. from the School of Pharmacy, University of London; 1987 and an MSc (1st in Class) in Biology, The Jagiellonian University of Cracow, Poland, 1979.

Zouhair M. Atassi, Ph.D., D.Sc., is currently a Professor of Biochemistry and Professor of Immunology at Baylor College of Medicine in Houston, Texas. He has many years of experience working with neurotoxins in the field of neurochemistry and immunology. A highly published scientist, he has authored over 400 papers. He is charged with assessing RPI-78 and RPI-MN in animal models of Myasthenia gravis and EAE.

Zheng-Hong Qin, MD, Ph.D., divides his time between Harvard University/Massachusetts General Hospital in Boston and Soochow University in Suzhou, China, where he conducts research on neurological disorders. His Chinese medical education has provided him with an important background on the use of anticholinergic peptides in medicine. He acts as a mediator in connection with studies conducted at Soochow University. Dr. Qin also conducts research for ReceptoPharm in such areas as pain and cancer in his research laboratories at Soochow University.

Additional ReceptoPharm Advisors

ReceptoPharm, Inc. has entered into agreements with consultants. All these specialists have indicated a willingness to join our Scientific Advisory Board in the future.

Thomas L. Lentz, MD, is currently Dean of Admissions at Yale University having taken this position fulltime. Prior to this post he was head of the Department of Cell Biology where he originated the theory that the Rabies virus employed the nicotinic receptor as the entry portal. Dr. Lentz and his groups published extensively on the subject. He has agreed to act as a consultant to ReceptoPharm with the option of joining the Scientific Advisory Board.